Via Cyte
Biotechnology, 5580 Morehouse Dr, San Diego, California, 92121, United States, 51-200 Employees
Phone Number: 85********
Who is VIACYTE
About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control t...
Read More
-
Headquarters: 5580 Morehouse Dr, San Diego, California, 92121, United States
-
Date Founded: 1999
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
ViaCyte Org Chart and Mapping
Fabian Nonis
Supervisor/Lead Senior Scientist in Cellular and Molecular Biology, Focused on Gene Editing Projects
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ViaCyte
Answer: ViaCyte's headquarters are located at 5580 Morehouse Dr, San Diego, California, 92121, United States
Answer: ViaCyte's phone number is 85********
Answer: ViaCyte's official website is https://viacyte.com
Answer: ViaCyte's revenue is $25 Million to $50 Million
Answer: ViaCyte's SIC: 2834
Answer: ViaCyte's NAICS: 325412
Answer: ViaCyte has 51-200 employees
Answer: ViaCyte is in Biotechnology
Answer: ViaCyte contact info: Phone number: 85******** Website: https://viacyte.com
Answer: About ViaCyte ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCytes product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. About ViaCytes Pipeline The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCytes PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month